statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an...

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

HC Wainwright reissued their buy rating on shares of Adicet Bio (NASDAQ:ACET - Free Report) in a research report report published on Tuesday, Benzinga reports. They currently have a $10.00 price...

HC Wainwright Reaffirms "Buy" Rating for Adicet Bio (NASDAQ:ACET)

Adicet Bio (NASDAQ:ACET - Get Free Report)s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga...

HC Wainwright Reiterates Buy Rating for Adicet Bio (NASDAQ:ACET)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Adicet Bio, Inc. (NASDAQ:ACET  Free Report)  Stock analysts at Wedbush lifted their Q1 2024 earnings estimates for Adicet Bio in a research report issued to clients and investors on...

Adicet Bio, Inc. to Post Q1 2024 Earnings of ($0.27) Per Share, Wedbush Forecasts (NASDAQ:ACET)

Key Financial Metrics Indicate Extended Cash Runway and Continued Pipeline DevelopmentRelated Stocks: ACET...

Adicet Bio Inc (ACET) Reports Q4 and Full Year 2023 Financial Results

Adicet Bio (NASDAQ:ACET  Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of...

Adicet Bio (NASDAQ:ACET) Releases Quarterly  Earnings Results, Beats Expectations By $0.03 EPS

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial...

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Volume	2.12M
52-Wk High	$7.50
52-Wk Low	$1.10

ACET Adicet Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals